Saturday Jun 21
Inflammatory genes in epicardial fat contiguous with coronary...
Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone.
Thu Jun 19, 2014
Legal-Bay Lawsuit Settlement Funding Reports $9 Billion in the first Actos (Pioglitazone) Settlement
Legal-Bay LLC, the Lawsuit Settlement Funding Company, disclosed today a new-implemented program involving lawsuit cash advances for clients facing complications due to risky Actos prescription drugs.
Tue Jun 17, 2014
A systems biology approach to understand the pathophysiological...
Cardiac pathological hypertrophy is associated with a significantly increased risk of coronary heart disease and has been observed in diabetic patients treated with rosiglitazone whereas most published studies do not suggest a similar increase in risk of cardiovascular events in pioglitazone-treated diabetic subjects.
Mon Jun 16, 2014
Medical News Today
GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide)...
Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Novo Nordisk A/S Combination Diabetes Drug IDegLira Effective After 1 Year Study
New One-year Data of IDegLira Shows Glucose-lowering Effect was Maintained for People With Type 2 Diabetes SAN FRANCISCO, Jun 14, 2014 -- SAN FRANCISCO, June 14, 2014 /PRNewswire/ - New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with ... (more)
Sat Jun 14, 2014
Applied Clinical Trials
New One-year Data of IDegLira Shows Glucose-lowering Effect was...
New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[ 1 ] Findings from the 26-week extension of the DUAL I clinical trial ... (more)
Tue Jun 10, 2014
Management of Patients Using Combination Therapy With Pioglitazone...
Current type 2 diabetes mellitus treatment involves progressive interventions from lifestyle changes to pharmacological therapies.
Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to...
More than 40 presentations including posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company diabetes portfolio at the American Diabetes Association's 74 th Scientific Sessions R in San Francisco, 13-17 June.